Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Streptococcal Dermatitis

The goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group A beta-hemolytic streptococci...

Date First Received: December 1, 2005

Last Updated: January 16, 2007

Verified by: University Children's Hospital Basel, January 2007

Clinical Trial Phase: Phase 4 | Start Date: October 2005

Overall Status: Terminated

Estimated Enrollment: 194

Brief Summary

Official Title: “Comparative Trial of Oral Penicillin Versus Cefuroxim for Treatment of Perianal Dermatitis - an Open, Randomized, Controlled Trial”

Condition Keyword(s):

The goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group A beta-hemolytic streptococci.

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study

Detailed Clinical Trial Description

The goal of the study is to investigate, which of two antibiotic treatments - oral penicillin for 10 days or oral cefuroxim for 7 days - is more successful for patients (1-16 years of age) with perianal dermatitis caused by group A beta-hemolytic streptococci (GABHS).

Diagnosis is based on positive perianal culture for GABHS. Informed consent will be obtained.

The study will be performed in the region of Basel, Switzerland, in private practices of pediatricians, general practitioners, and selected pediatric dermatologists as well as in the out-patient departments of the University Children's Hospital Basel and the department for dermatology of the University of Basel.

Patients (or their parents) will fill in a daily diary on signs and symptoms of disease; furthermore, clinical investigations (inspection of the site of infection) will be performed on enrollment (Day 1), Day 3, and at the end of treatment (Day 10).

Intervention(s) in this Clinical Trial

  • Drug: Penicillin versus cefuroxim per os

Outcome Measures for this Clinical Trial

Primary Measures

  • Resolving signs and symptoms of perianal dermatitis

Secondary Measures

  • microbiological cure (= negative culture for GABHS) at end of treatment

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • informed consent
  • age 1-16 years
  • typical clinical symptoms for perianal dermatitis
  • positive perianal culture for GABHS

Exclusion Criteria:

  • antibiotic treatment in previous 14 days
  • immunodeficiency
  • penicillin allergy
  • cephalosporin allergy
  • further bacterial infections

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 1 Year

Maximum Age for this Clinical Trial: 16 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: University Children's Hospital Basel

Overall Clinical Trial Officials and Contacts

Ulrich Heininger, MD Principal Investigator University Children's Hospital Basel  

Related Publications

References

Landolt M, Heininger U. [Prevalence of perianal streptococcal dermatitis in children and adolescents] Schweiz Rundsch Med Prax. 2005 Sep 21;94(38):1467-71. German.

Additional Information

Information obtained from ClinicalTrials.gov on December 03, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00261742

Study ID Number: 214/05

ClinicalTrials.gov Identifier: NCT00261742

Health Authority: Switzerland: Swissmedic

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.